Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 10/20 | 0.67 |
| ▸ | F2 | P00734 | 8/20 | 0.65 |
| ▸ | PLAU | P00749 | 4/20 | 0.56 |
| ▸ | ST14 | Q9Y5Y6 | 3/20 | 0.55 |
| ▸ | HPN | P05981 | 1/20 | 0.55 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.55 |
| ▸ | PLG | P00747 | 2/20 | 0.54 |
| ▸ | PLAT | P00750 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20560100 | 1.00 | F10 (0.67) | F10F2PLAUST14HPN | |
| Hydrochloric Acid SCHEMBL1329733 | 0.99 | F10 (0.66) | F10F2PLAUST14HPN | |
| SCHEMBL1328461 | 0.90 | PLG (0.57) | F10PLAUST14HPNHGFAC | |
| SCHEMBL20560096 | 0.90 | PLG (0.57) | F10PLAUST14HPNHGFAC | |
| SCHEMBL10309164 | 0.89 | PLAU (0.69) | F10F2PLAUST14PLG | |
| SCHEMBL29692600 | 0.89 | PLAU (0.69) | F10F2PLAUST14PLG | |
| SCHEMBL20560510 | 0.89 | PLAU (0.69) | F10F2PLAUST14PLG | |
| Hydrochloric Acid SCHEMBL29808155 | 0.88 | PLAU (0.68) | F10F2PLAUST14PLG | |
| SCHEMBL1460406 | 0.87 | F2 (0.56) | F10F2PLAUST14HPN | |
| SCHEMBL18594808 | 0.86 | F2 (0.54) | F10F2PLAUST14HPN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2349241-B1 | PHARMACEUTICAL COMPOSITIONS WITH ATTENUATED RELEASE OF PHENOLIC OPIOIDS | SIGNATURE THERAPEUTICS INC (US) | 2019-06-19 | — | — | EP | claimed |
| EP-2560486-B1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF | SIGNATURE THERAPEUTICS INC (US) | 2018-11-21 | — | — | EP | claimed |
| US-9534014-B2 | Pharmaceutical compositions with attenuated release of phenolic opioids | SIGNATURE THERAPEUTICS, INC. (US) | 2017-01-03 | — | — | US | claimed |
| EP-2663187-B1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OXYCODONE PRODRUG | SIGNATURE THERAPEUTICS INC (US) | 2016-06-01 | — | — | EP | claimed |
| US-9238020-B2 | Compositions comprising enzyme-cleavable phenol-modified tapentadol prodrug | SIGNATURE THERAPEUTICS, INC. (US) | 2016-01-19 | — | — | US | claimed |
| US-8962547-B2 | Compositions comprising enzyme-cleavable oxycodone prodrug | SIGNATURE THERAPEUTICS, INC. (US) | 2015-02-24 | — | — | US | claimed |
| US-20150031635-A1 | Pharmaceutical Compositions with Attenuated Release of Phenolic Opioids | 3I, LP | 2015-01-29 | — | — | US | claimed |
| US-8802681-B2 | Pharmaceutical compositions with attenuated release of phenolic opioids | SIGNATURE THERAPEUTICS, INC. (US) | 2014-08-12 | — | — | US | claimed |
| US-20140162935-A1 | Compositions Comprising Enzyme-Cleavable Oxycodone Prodrug | SIGNATURE THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | claimed |
| EP-2663187-A2 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OXYCODONE PRODRUG | Signature Therapeutics, Inc. (US) | 2013-11-20 | — | — | EP | claimed |
| US-8497237-B2 | Compositions comprising enzyme-cleavable oxycodone prodrug | SIGNATURE THERAPEUTICS, INC. (US) | 2013-07-30 | — | — | US | claimed |
| US-20130089504-A1 | Compositions Comprising Enzyme-Cleavable Hydromorphone Prodrug | SIGNATURE THERAPEUTICS, INC. (US) | 2013-04-11 | — | — | US | claimed |
| WO-2012096886-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OXYCODONE PRODRUG | SIGNATURE THERAPEUTICS, INC. (US) | 2012-07-19 | — | — | WO | claimed |
| WO-2012096887-A2 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OXYCODONE PRODRUG | SIGNATURE THERAPEUTICS, INC. (US) | 2012-07-19 | — | — | WO | claimed |
| US-20120178773-A1 | Compositions Comprising Enzyme-Cleavable Oxycodone Prodrug | 3I, LP | 2012-07-12 | — | — | US | claimed |
| US-20120178772-A1 | Compositions Comprising Enzyme-Cleavable Oxycodone Prodrug | 3I, LP | 2012-07-12 | — | — | US | claimed |
| US-20110281886-A1 | Pharmaceutical Compositions with Attenuated Release of Phenolic Opioids | 3I, LP | 2011-11-17 | — | — | US | claimed |
| WO-2011133179-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE HYDROMORPHONE PRODRUG | PHARMACOFORE, INC (US) | 2011-10-27 | — | — | WO | claimed |
| EP-2349241-A1 | PHARMACEUTICAL COMPOSITIONS WITH ATTENUATED RELEASE OF PHENOLIC OPIOIDS | Pharmacofore, Inc. (US) | 2011-08-03 | — | — | EP | claimed |
| WO-2010045599-A1 | PHARMACEUTICAL COMPOSITIONS WITH ATTENUATED RELEASE OF PHENOLIC OPIOIDS | PHARMACOFORE, INC. (US) | 2010-04-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031635-A1 | Pharmaceutical Compositions with Attenuated Release of Phenolic Opioids | COMT, OPRM1, OPRK1 | F10 2774/4885F2 1569/4885PLAU 495/4885 |
| US-20130089504-A1 | Compositions Comprising Enzyme-Cleavable Hydromorphone Prodrug | TMPRSS15, DNPEP, PGA5 | F10 1427/4885F2 843/4885PLAU 82/4885 |
| US-20120178773-A1 | Compositions Comprising Enzyme-Cleavable Oxycodone Prodrug | OPRK1, CYP3A7, OPRD1 | F10 3539/4885F2 2591/4885PLAU 816/4885 |
| US-20110281886-A1 | Pharmaceutical Compositions with Attenuated Release of Phenolic Opioids | COMT, OPRM1, OPRK1 | F10 2774/4885F2 1569/4885PLAU 495/4885 |
| US-20120178772-A1 | Compositions Comprising Enzyme-Cleavable Oxycodone Prodrug | OPRK1, KDM8, ADAM8 | F10 3253/4885F2 1193/4885PLAU 685/4885 |
| US-20140162935-A1 | Compositions Comprising Enzyme-Cleavable Oxycodone Prodrug | OPRK1, KDM8, ADAM8 | F10 3253/4885F2 1193/4885PLAU 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.